Compare LCFY & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCFY | BIVI |
|---|---|---|
| Founded | 2009 | 2013 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 9.2M |
| IPO Year | 2022 | N/A |
| Metric | LCFY | BIVI |
|---|---|---|
| Price | $3.25 | $1.23 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 122.3K |
| Earning Date | 03-13-2026 | 02-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,099,713.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.51 | $1.10 |
| 52 Week High | $13.98 | $20.40 |
| Indicator | LCFY | BIVI |
|---|---|---|
| Relative Strength Index (RSI) | 46.67 | 42.40 |
| Support Level | $3.09 | $1.17 |
| Resistance Level | $3.81 | $1.25 |
| Average True Range (ATR) | 0.45 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 5.89 | 30.43 |
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.